<DOC>
	<DOCNO>NCT01951144</DOCNO>
	<brief_summary>The purpose study healthy people evaluate safety , toleration time course plasma concentration single oral dos PF-06372865 . The pharmacodynamic activity PF-06372865 also assess . The effect food PK PK PF-06372865 administer tablet formulation may also investigate . Pharmacodynamic interaction PF-06372865 lorazepam evaluate .</brief_summary>
	<brief_title>A First In Human Study In Healthy People To Evaluate Safety , Toleration , Pharmacokinetics Pharmacodynamics Single Oral Doses Of PF-06372865</brief_title>
	<detailed_description />
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Healthy male subject female subject nonchild bear potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Toleration</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>